These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 25520081)
41. Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy. Peng JW; Lin GN; Xiao JJ; Jiang XM Asia Pac J Clin Oncol; 2012 Dec; 8(4):356-61. PubMed ID: 22897940 [TBL] [Abstract][Full Text] [Related]
42. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching. Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952 [TBL] [Abstract][Full Text] [Related]
43. Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study. Sun F; Liu Z; Wang B BMC Cancer; 2021 Oct; 21(1):1103. PubMed ID: 34649509 [TBL] [Abstract][Full Text] [Related]
44. Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study. Yeh ML; Huang CI; Hsieh MY; Huang CF; Hsieh MH; Huang JF; Dai CY; Lin ZY; Chen SC; Yu ML; Chuang WL Kaohsiung J Med Sci; 2016 Nov; 32(11):559-566. PubMed ID: 27847098 [TBL] [Abstract][Full Text] [Related]
45. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857 [TBL] [Abstract][Full Text] [Related]
46. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. Liu F; Chen L; Yu DM; Deng L; Chen R; Jiang Y; Chen L; Huang SY; Yu JL; Gong QM; Zhang XX Gut; 2011 Sep; 60(9):1269-77. PubMed ID: 21292683 [TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Lee KS; Kweon YO; Um SH; Kim BH; Lim YS; Paik SW; Heo J; Lee HJ; Kim DJ; Kim TH; Lee YS; Byun KS; Kim D; Lee MS; Yu K; Suh DJ Clin Mol Hepatol; 2017 Dec; 23(4):331-339. PubMed ID: 28946736 [TBL] [Abstract][Full Text] [Related]
48. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study. Maklad S; Doss W; El Din SS; Hassan K; Zeid AA Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505 [TBL] [Abstract][Full Text] [Related]
49. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis. Yue-Meng W; Li YH; Wu HM; Yang J; Xu Y; Yang LH; Yang JH Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312 [TBL] [Abstract][Full Text] [Related]
50. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455 [TBL] [Abstract][Full Text] [Related]
51. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy. Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767 [TBL] [Abstract][Full Text] [Related]
52. Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. Kim HS; Kim BK; Kim SU; Park JY; Kim DY; Song KJ; Park JW; Kim YJ; Baatarkhuu O; Han KH; Ahn SH Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1647-1656.e6. PubMed ID: 27305847 [TBL] [Abstract][Full Text] [Related]
53. Genotype Matters in Patients with Acute-on-chronic Liver Failure Due to Reactivation of Chronic Hepatitis B. Wan YM; Li YH; Xu ZY; Wu HM; Wu XN; Xu Y Clin Transl Gastroenterol; 2018 Nov; 9(11):202. PubMed ID: 30416197 [TBL] [Abstract][Full Text] [Related]
54. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. Kurokawa M; Hiramatsu N; Oze T; Yakushijin T; Miyazaki M; Hosui A; Miyagi T; Yoshida Y; Ishida H; Tatsumi T; Kiso S; Kanto T; Kasahara A; Iio S; Doi Y; Yamada A; Oshita M; Kaneko A; Mochizuki K; Hagiwara H; Mita E; Ito T; Inui Y; Katayama K; Yoshihara H; Imai Y; Hayashi E; Hayashi N; Takehara T J Gastroenterol; 2012 May; 47(5):577-85. PubMed ID: 22231575 [TBL] [Abstract][Full Text] [Related]
55. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117 [TBL] [Abstract][Full Text] [Related]
56. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH; Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134 [TBL] [Abstract][Full Text] [Related]
57. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327 [TBL] [Abstract][Full Text] [Related]
58. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy. Su CW; Wu CY; Hung HH; Wu CH; Sheen IJ; Wu JC J Gastroenterol Hepatol; 2013 Dec; 28(12):1849-58. PubMed ID: 23730852 [TBL] [Abstract][Full Text] [Related]
59. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL; J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191 [TBL] [Abstract][Full Text] [Related]
60. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F; Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]